Duloxetine Pellet Separating Layer Prevents Ionic Interaction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing pharmaceutical formulations, particularly those containing duloxetine hydrochloride, face challenges in achieving complete release and gastric juice resistance due to interactions between cationic active ingredients and anionic polymers, leading to incomplete dissolution and potential toxicity in acidic environments.

Innovation Solution

A pharmaceutical preparation in pellet form with a core containing duloxetine hydrochloride, a separating layer of an ester of optionally substituted cellulose with organic acids, and an enteric layer comprising a (meth)acrylic acid-containing polymer, along with an inner protective layer of sugar, is developed to prevent interactions and ensure complete release in the digestive tract.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If an enteric layer comprising anionic polymers is used to achieve gastric juice resistance, then protection from stomach acid is improved, but interactions with cationic active ingredients lead to incomplete dissolution

Engineering Contradiction:
Improvegastric juice resistanceVSAvoiddissolution completeness
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

A separating layer comprising a polymer with both carboxyl and hydroxyl groups is introduced between the enteric layer (anionic polymer) and the active ingredient (cationic compound). This intermediary layer prevents direct interaction between the anionic and cationic components, eliminating the formation of insoluble complexes while maintaining the enteric coating's gastric juice resistance. The separating layer acts as a buffer that avoids both ionic cross-linking and hydrogen bonding that would otherwise occur.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The coating system is divided into distinct functional layers: an enteric layer for gastric juice resistance, a separating layer to prevent interactions, and an active ingredient core. This segmentation allows each layer to perform its specific function independently, with the separating layer specifically designed to block harmful interactions between the enteric polymer and the cationic active ingredient.

Inventive Principle:
Principle #1Segmentation

2Object-affected harmful factors

If conventional separating layers are used to prevent interactions, then direct contact between active ingredients and enteric polymers is reduced, but incomplete release and potential toxicity remain in acidic environments

Engineering Contradiction:
Improveinteraction preventionVSAvoidrelease completeness
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The separating layer polymer is specifically selected to have dual functionality with both carboxyl and hydroxyl groups, creating a unique chemical parameter profile that differs from conventional separating layers. This dual-group polymer maintains pH-dependent solubility characteristics while preventing ionic interactions, ensuring complete drug release across different pH conditions including acidic environments.

Inventive Principle:
Principle #35Parameter changes

3Stability of the object's composition

If enteric-coated formulations are used to protect acid-labile active ingredients, then stability in stomach acid is improved, but incomplete dissolution occurs due to ionic interactions

Engineering Contradiction:
Improveacid stabilityVSAvoiddissolution rate
Core Design Contradiction:
Stability of the object's compositionVSManufacturing precision

Solution Approach 1:

The separating layer serves as a mediator that preserves the enteric coating's acid stability function while preventing the ionic interaction that causes dissolution problems. The carboxyl-hydroxyl polymer in the separating layer blocks the electrostatic attraction between the anionic enteric polymer and cationic active ingredient, allowing the enteric layer to maintain its protective function without compromising dissolution.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentEP2453880B1Separating layers for pharmaceutical preparations to prevent interactions between medicinal drugs and pharmaceutical-technological adjuvants
Publication Date: 2019.02.13 ADD TECH
  • EP2453880B1 patent drawingFigure 1
  • EP2453880B1 patent drawingFigure 2

AI summary

The invention relates to a granular pharmaceutical preparation comprising a core containing an active substance, comprising duloxetine or a pharmaceutically acceptable salt thereof, an optional first separating layer over the core, a second separating layer over the first separating layer, said second separating layer being different from the first separating layer and comprising an ester made of optionally substituted cellulose with one or more organic acids, and an enteric-coated layer, which is different from the first and the second separating layers and comprises a (meth)acrylic acid-containing polymer and forms the outer layer of the composition.